Sun Pharmaceutical Industries Limited — Others, 31-07-2025: Shareholders meeting

Sun Pharma shareholders have approved a final dividend of Rs. 5.50 per share at the 33rd Annual General Meeting. The company reported strong FY25 results with revenue up 9% to ₹52,000 Cr and adjusted net profit up 19% to ₹12,000 Cr. Global Specialty revenue surged 17.1% to US$1.216 billion. India sales grew 13.7% to ₹16,900 Cr, and US sales increased 5.8% to ₹16,200 Cr. For FY26, Sun Pharma anticipates mid to high single-digit topline growth. A significant leadership transition was also approved, with Mr. Kirti Ganorkar appointed as the new Managing Director.